

Newsletter from Emotra AB (publ)

Göteborg, September 26, 2016

Emotra – Lars-Håkan Thorell praised by ECNP

This past week Lars-Håkan Thorell, the inventor of EDOR® and Emotra's Head of research, has received a great deal of attention for his many years of research into identifying patients who are at risk of committing suicide. Thorell has been voted in as a member of the *European College of Neuropsychopharmacology, ECNP*. On Tuesday, September 20, Doctor Thorell held a much acclaimed induction speech for the other members at their conference in Vienna.

In the audience that Lars-Håkan Thorell addressed was Professor Marco Sarchiapone, from Molise, Italy, who is President of the *European Psychiatric Association's Suicide Section, EPA-SS*. The Suicide Section is EPA's largest and most active section, with members from no less than 27 countries.

The EPA and ECNP are the two leading organisations for psychiatric specialists in Europe. Of the two bodies, EPA's profile is more academic, while ECNP, which was created on the pharmaceutical industry's initiative, focuses more on clinical practice. Emotra already has a far-reaching and well-functioning collaboration with EPA's suicide section. The ECNP now choosing to offer Lars-Håkan Thorell a membership is another feather in the hat for Emotra in anticipation of the launch of EDOR® during the spring of 2017.

Emotra's strategy is entirely based on working together with important psychiatric organisations and to collaborate with leading persons in the discipline. If we are to succeed with this strategy, confidence in the Company and its EDOR® method must be as strong as possible.

One of the most important and crucial components in building this confidence is, of course, that our ongoing multi-centre study, EUDOR-A, which involves more than 50 researchers from 18 different European clinics and comprises 1,573 patients ranging from 18 to 92 years of age, produces the results we are all hoping for. Our review of the baseline material indicates that the study set-up is according to plan, which gives us high hopes for the final study results. In addition to this, two research teams who are both participating in our EUDOR-A study recently presented results that further underscore importance of hyporeactivity in the identification of patients at risk of attempting suicide.

On March 11, 2017, all of our study patients will have been followed for 12 months after testing, thus concluding our study period.

We will be holding a wind-down meeting in Rome, Italy, on March 29, 2017. The object of this meeting is to reach a consensus agreement on the method's reliability, safety and usability. On April 4–5, 2017, the study results will be presented at a global conference in Florence, Italy.

"Ever since we first presented EDOR® and the possibilities it provides to assess suicide risk, interest in this method has been growing steadily, and the reception of Lars-Håkan Thorell's presentation at the ECNP could not have been better", Professor Marco Sarchiapone states. "Among all the questions the audience asked, I did not notice any of the scepticism that is usually quite normal. On the contrary, everyone there showed their appreciation of all the years that Lars-Håkan Thorell has dedicated to

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR®, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.

Emotra AB (publ), Göteborgsvägen 74, SE-433 63 Sävedalen, Sweden

Tel: +46 708 25 45 47, www.emotra.se



understanding how to identify patients who are at risk of committing suicide. Furthermore, the audience consistently praised the ambitious set-up of our EUDOR-A study and that Emotra is carrying it out in an open collaboration with EPA-SS. Several researchers showed an interest in participating in our continued progress and even suggested new studies to examine other psychopathological dimensions of suicide. There is no functional alternative to EDOR®, so everyone views the method as the best opportunity in the foreseeable future for the psychiatric discipline to find a viable diagnostic method for identifying suicide risk. In addition, the group was very optimistic about the possibility of our EUDOR-A to produce the expected results, even if we can never be completely certain until we have collected and statistically analysed all the follow-up data”, Professor Sarchiapone continues.

As far as Emotra is concerned, Lars-Håkan Thorell’s induction as a member of this illustrious group is a huge success. It is a step in the establishment of a collaboration with the ECNP, the other large international organisation in the area of psychiatric and neurological research.

“The conclusions from our baseline material have further raised our expectations”, Professor Sarchiapone states. “All previous observations in our very extensive material (1,573 patients) have been confirmed. This is very important, since previous studies have been too small to be statistically reliable. One interesting observation from our baseline material is the high conformance between EDOR® test results and the profession’s earlier clinical assessments.”

Collaboration with leading organisations and prominent representatives for the psychiatric profession are crucial factors for Emotra, and the Company’s whole business concept is based on the success of this strategy.

“Ever since I heard about EDOR® at my first meeting with Emotra in the autumn of 2013, I have believed in the possibility of solving the greatest dilemma in suicide research: identifying those patients who are at risk of committing suicide”, Marco Sarchiapone says. “The Company and I immediately agreed that proving the method is reliable enough to be used in clinical practice would require a large clinical study. I have never had any doubts since then. We are fully aware that the final study results will determine how reliable the method is, but by showing that they, as a company, are prepared to openly cooperate with our organisation, Emotra has gained our trust. That was a crucial factor for many clinics in their decision to get on board and collaborate on this important project”, Sarchiapone says in closing.

Later this autumn, Lars-Håkan Thorell will be presenting his research results in Chicago as one of the invited keynote speakers at a large and important international conference on bipolar disorders.

Emotra’s CEO, Claes Holmberg, presented Emotra at MTI in London, England on September 20–21. He will also be holding a presentation of the company at the Swedish Shareholders’ Association’s meeting in Falköping on October 17 and at Stora Aktiedagen on November 14 in Göteborg.

For further information, please contact: Claes Holmberg, CEO. Telephone: +46 708 25 45 47, E-mail: claes@emotra.se

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company’s method, EDOR®, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient’s response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.

Emotra AB (publ), Göteborgsvägen 74, SE-433 63 Sävedalen, Sweden
Tel: +46 708 25 45 47, www.emotra.se